meridianmarketconsultants-blog - Tumblr blog

[meridianmarketconsultants-blog]

Voice User Interface for Mobile Apps or Smart Home Speakers are becoming increasingly Popular in Today’s Technology

Meridian Market Consultants (MMC) has published a new report titled, “Voice User Interface Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Voice User Interface Market, by Technology (AI Based & Non-AI Based) by Industry (Automotive, BFSI, Consumer, Education, Enterprise, Government, Healthcare, Legal, Military, Retail, Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa)is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Voice User Interface Market, click the link below:

https://www.meridianmarketconsultants.com/global-voice-user-interface-market

As per the report, rapid technological changes along with quick adoption of new technologies is attributed to the growth of voice user interface market. From punch cards to keyboards, from mouse to touch screens, technologies have transformed the way humans can interact with the machine. Interaction is the first revolution that occurred in the development of the human-machine interface. Voice user interface is one the big step towards the second revolution in human-machine interface. Voice enables a convenient integration. It is hands-free, keyboard-free and eyes-free. Talking is natural and does not require the user to learn new skills. Hence the learning curve in voice-user interface is low. Also, voice interaction can be quickly adopted by today’s generations, disabled and elderly people, etc. Hence, a voice user interface is witnessing quick adoption in the global market. Voice interaction can be easily used in situations where other interactions can’t be used for instance while driving and walking, in dark, etc. These advantages are making voice user interface increasingly popular media for human-machine interaction.

For requesting free sample and PDF Brochure related to our latest study on Global Voice User Interface Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=9172

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=9172

Furthermore, Meridian Market Consultants (MMC) Study identifies that voice user interface market is expected to experience unprecedented growth rate during the forecast period. Voice recognition was first introduced in the 1920s when a toy dog "Radio Rex" could come when his name was called. Voice user interface was also used in vehicles. However, the poor recognition accuracy and bad user experiences restricted it from going further. Machine learning significantly improved the accuracy of voice recognition in the 2010s. For instance, in 2016, Microsoft reported significant improvement in voice recognition, and in 2017 Google reported 95% accuracy in voice recognition. The technology improvement indicates that machines can be as good as human beings in terms of "hearing" and now voice recognition has become a commodity. However, speech is language-dependent and this makes the global market more complicated and segmented. Generally, the global market is focused on English-centric interactions. All five big technology companies such as Apple, Google, Microsoft, Amazon, Facebook have developed voice-enabled AI assistants. One such AI assistance Siri is helping over 40 million people per month. According to ComScore, one in ten households in the U.S. own a smart speaker.

MMC Study identifies some of the key participating players in Voice User Interface market globally are Agnitio S.L., Advanced Voice Recognition Systems, Inc., Apple, Inc., Baidu, Inc., Amazon, Inc., BioTrust ID B.V., CastleOS Software, LLC, Facebook, Inc., Google, Inc. and Microsoft Corporation, among others.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Advances in Genomics enabled more Efficient Treatment Approaches for Complex Diseases

Meridian Market Consultants (MMC) has published a new report titled, “Complex Disease Treatment Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Complex Disease Treatment Market, by Disease (Asthma, Diabetes, Epilepsy, Hypertension, Manic Depression, Schizophrenia, Others) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Complex Disease Treatment Market, click the link below:

https://www.meridianmarketconsultants.com/global-complex-disease-treatment-market

As per the report, complex diseases are diseases which progress in severity and are difficult to treat by drugs. Complex diseases are caused by a combination of genetic, environmental, and lifestyle factors, most of which have not yet been identified. List of such diseases is long and some of them include congestive heart failure, aneurysm, diabetes, kidney diseases, cancers, congenital defects, scleroderma, Alzheimer's disease, Parkinson's disease, asthma, multiple sclerosis, etc. Understanding disease causes and drug action at the molecular and systems levels could help to identify combinations of drugs that are more effective than individual drugs alone. Current approaches to complex disease treatment have reached their limits, and medicine now requires new thinking to derive drug discovery and usage. Scientists now know that complex diseases do not obey the standard Mendelian patterns of inheritance. Although associated genes are inherited, genetic factors are only part of risk factors. Hence, understanding gene-environment interactions improve knowledge of complex disease causes, and more efficient treatment can be developed.

For requesting free sample and PDF Brochure related to our latest study on Global Complex Disease Treatment Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=2645

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=2645

Furthermore, Meridian Market Consultants (MMC) Study identifies that complex disease requires complex treatment and advances in genomics, proteomics, etc. has enabled the discovery of new targeted therapies. Several treatment options now available for the treatment of complex diseases include gene therapy, biologic therapy, chemotherapy, microbiome therapy, targeted therapy, etc. among others. Understanding of systems-biology has enabled the understanding of complex network underlying many diseases such as heart disease, kidney disease, diabetes, metabolic diseases, and cancers. In case of cardiovascular diseases, there is most likely a genetic component involved, but the role of comorbidities such as diabetes, kidney disease, etc. is not yet well elucidated. Hence, the treatment of such a complex disease requires a multidisciplinary approach. Most of the drugs known today for complex disease treatment work at the molecular level. These treatments are propagated across scales of the organization to alter tissue or organ function to cure or relieve disease.

MMC Study identifies some of the key participating players in Complex Disease Treatment market globally are Regeneron Pharmaceuticals, Novo Nordisk, UCB, Solvay Pharmaceuticals, and Allergan, etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to providing deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Unruptured Intracranial Aneurysm Treatment Market is Expected to Witness Significant Growth due to Latest Technological Advances in Aneurysm Treatment

Meridian Market Consultants (MMC) has published a new report titled, “Unruptured Intracranial Aneurysm Treatment Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Unruptured Intracranial Aneurysm Treatment Market, by Treatment Type (endovascular therapy, Surgical clipping, Flow diversion stents, medicines), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Unruptured Intracranial Aneurysm Treatment Market, click the link below:

https://www.meridianmarketconsultants.com/global-unruptured-intracranial-aneurysm-market

As per the report, hypertension is identified as the major risk factor for intracranial aneurysm, and mounting prevalence of hypertension is in part attributed to the growth of unruptured intracranial aneurysm treatment market. Some other risk factors for an intracranial aneurysm are cigarette smoking, genetic predisposition, trauma/injury to cranial blood vessels, blood infection, etc. Intracranial aneurysm is a cerebrovascular disorder characterized by bulging or localized dilation of a cerebral artery due to weakness in the wall of the artery. Unruptured intracranial aneurysms (UIA) are a common finding and occur in about 2% of the population. The estimated prevalence of unruptured intracranial aneurysms is approximately 3.2% in the general population but may be higher in older patients, females, and patients with a family history or certain genetic conditions. If less than 10 mm, unruptured aneurysms often remain asymptomatic. The large aneurysm can present with symptoms including headache, seizure, cranial nerve palsies, cerebral ischemic events, etc. Aneurysm rupture resulting in subarachnoid hemorrhage (SAH) is the most serious consequence of unruptured intracranial aneurysm. Subarachnoid hemorrhage occurs at a rate of approximately 6–10/100,000 person-years. The fatality rate for subarachnoid hemorrhage is around 30% to 40%.

For requesting free sample and PDF Brochure related to our latest study on Global Unruptured Intracranial Aneurysm Treatment Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=3478

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=3478

Furthermore, Meridian Market Consultants (MMC) Study identifies that surgical clipping of the aneurysm is the most common treatment type for unruptured intracranial aneurysm. Until 1995, surgical clipping was the only method available for the treatment of an unruptured intracranial aneurysm. However, recent technological advances such as the introduction of less invasive endovascular therapy and flow diversion stents would push the market for unruptured intracranial aneurysm treatment. Endovascular therapy involves coiling of the aneurysm. These coils are deployed into an aneurysm via a microcatheter that is inserted through the femoral artery of the leg and gradually advanced into the brain. Endovascular therapy/coiling is expected to be the choice of treatment for unruptured intracranial aneurysm because it does not require an opening of the skull and require less time. However, it renders the chances of recanalization. Hence, surgical clipping is still preferred over endovascular therapy. Flow diversion stents were introduced in the 2000s. Antihypertensive medicines are recommended in patients with hypertension and unruptured intracranial aneurysm, along with diet and exercise program.

MMC Study identifies some of the key participating players in unruptured intracranial aneurysm treatment market globally are ev3 Inc., Balt USA LLC., Stryker Corporation, MicroVention, Inc., Aesculap, Inc. (B. Braun), adeor medical AG, C R Bard, Penumbra, Inc., DePuy Synthes, etc,

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Advances in Technology would push the Market for Cognitive Dysfunction Devices

Meridian Market Consultants (MMC) has published a new report titled, “Cognitive Dysfunction Devices Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Cognitive Dysfunction Devices Market, by Product Type (hearing aids, voice recognition devices, pill dispensers & reminders, prostheses, mobility aids), By Distribution Channel (Hospitals, clinics, e-commerce, rehabilitation centers), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Cognitive Dysfunction Devices Market, click the link below:

https://www.meridianmarketconsultants.com/global-cognitive-dysfunction-devices-market

As per the report, rise in prevalence of dementia and Alzheimer’s disease is attributed to the growth of cognitive dysfunction devices market. According to WHO estimates the worldwide prevalence of dementia in the population above 60 years is 5% to 8%. In Canada these rates re as high as 14.9% for the age 65 and above. Cognitive dysfunction or cognitive impairment is associated with dementia and Alzheimer’s disease. Over 20 million individuals have a cognitive disability in the U.S. Moreover, improving life expectancy is also contributing to increased prevalence of cognitive dysfunctions. In the U.S. there are over 526,000 individuals over 60 years of age with mental retardation and other developmental disabilities. Some other risk factors for cognitive dysfunction are attention deficit hyperactivity disorder (ADHD), traumatic brain injury, Cerebral Vascular Incidents (CVA), Autism, stroke, etc. Traumatic brain injury can affect different cognitive functions such as memory, language, reasoning, learning, etc. About 2 million people in the U.S. have a brain injury every year, and about 10% of those have long term cognitive deficits which interfere with their everyday functioning.

For requesting free sample and PDF Brochure related to our latest study on Global Cognitive Dysfunction Devices Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=3854

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=3854

Furthermore, Meridian Market Consultants (MMC) Study identifies that, cognitive dysfunction devices are commonly used by elderly patients. These devices may help to slow functional decline in this population and help prevent patients from becoming more seriously ill. Cognitive dysfunction devices can significantly compensate for physical and sensory deficits, but they may pose risks to health and safety if not used properly. Cognitively impaired patients are found to use these devices for their physical impairment mainly because of worries relating to safety. Cognitive dysfunction devices can be customized to patient’s needs. However, the lack of training for assistive device use explains the lower rate of device use among geriatric patients with cognitive deficits. The study conducted in Sweden concluded that the more complex the technology, the less likely are elders with cognitive impairments to use it effectively.

MMC Study identifies some of the key participating players in cognitive dysfunction devices market globally are Siemens AG, Signia, Rexton, HearUSA, Phonak (Sonova), Starkey, Sonic Innovations, Belton, Oticon, Unitron, Bernafon, Earnet, Hansaton, Interton, etc. among others.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Healthcare is emerging as a Prominent Area for Artificial Intelligence Research and Applications

Meridian Market Consultants (MMC) has published a new report titled, “Artificial Intelligence (AI) in Healthcare Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Artificial Intelligence (AI) in Healthcare Market, by Service Type (AI in Diagnosis, AI in Decision making, AI in Treatment, AI in Research, AI in Training & Education), By End Users (Hospitals, Diagnostic Centers, Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Artificial Intelligence (AI) in the Healthcare Market, click the link below:

https://www.meridianmarketconsultants.com/global-artificial-intelligence-in-healthcare

As per the report, mounting demand for robotics and automation in healthcare industry is attributed to the growth of artificial intelligence in healthcare market. AI is getting increasingly sophisticated at doing what humans do, but more efficiently, more quickly and at a lower cost. There exists a vast potential for AI in healthcare. In healthcare, AI can be employed at various nodes of the healthcare value chain such as early detection and diagnosis, decision making, treatment, end of life care, research, training, and education, etc. Artificial intelligence improves the ability of healthcare professionals to better understand the day-to-day pattern and patient needs. Even pharmaceutical companies are experimenting with AI to design new drugs. For instance, Merck is developing a new drug with the application of AI in partnership with  Atomwise. GlaxoSmithKline partnered with Insilico Medicine for in silico drug design and development using AI. Since 2013, healthcare AI startups have raised approximately US$ 4.3 billion across 576 deals. Healthcare tops all other industries in terms of AI deals. However, AI in healthcare faces technical and feasibility challenges.

For requesting free sample and PDF Brochure related to our latest study on Global Artificial Intelligence (AI) in Healthcare Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=1328

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=1328

Furthermore, Meridian Market Consultants (MMC) Study identifies that transformative power of AI in healthcare is truly life-changing. From hospital care to clinical research, drug development and insurance, AI applications are revolutionizing how the health sector works to reduce spending and improve patient outcomes. According to Forbes, the total public and private sector investment in healthcare AI are expected to reach US$ 6.6 billion by 2021. In AI in diagnostics such as image recognition has revolutionized the diagnostics industry. For instance, Google DeepMind’s artificial neural network is working closely with researchers and clinicians. Recently, DeepMind’s neural networks matched the accuracy of medical experts in diagnosing 50 sight-threatening eye diseases. AI in treatment can help clinicians to take a more comprehensive approach for treatment planning, disease management, coordinated care plans, etc. Robots have been used in medicine for more than 30 years, ranging from simple laboratory robots to complex surgical robots.  Robotic surgery is already taking medicine to the next level. Robots also have the potential to help end of life care, helping people to remain independent for longer and reducing the need for hospitalization. Drug discovery and development is one of the more recent applications for AI in healthcare. AI in drug discovery has significantly reduced the time to market for new drugs. With the power of AI embedded in smartphones, training and education can be done anywhere.

MMC Study identifies some of the key participating players in Artificial Intelligence (AI) in Healthcare market globally are Google Inc., Apple Inc., Cognizant Technology Solutions, Siemens, Infosys, Dell, Atomwise, Insilico Medicine, Samsung, GNS Healthcare, etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Surgical Resection is expected to account for Highest Share in Malignant Peripheral Nerve Sheath Tumor Treatment Market

Meridian Market Consultants (MMC) has published a new report titled, “Malignant Peripheral Nerve Sheath Tumor Treatment Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Malignant Peripheral Nerve Sheath Tumor Treatment Market, by Treatment Type (Surgery, Radiation Therapy, Chemotherapy), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a healthy CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Malignant Peripheral Nerve Sheath Tumor Treatment Market, click the link below:

https://www.meridianmarketconsultants.com/global-malignant-peripheral-nerve-sheath-tumor-treatment

As per the report, the mounting incidence of soft tissue sarcoma and improving diagnosis rates are the major factors attributed to the growth of malignant peripheral nerve sheath tumor treatment market. Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath. Malignant peripheral nerve sheath tumors can originate from multiple cells such as Schwann cells, perineural cells, or fibroblasts. Hence the tumor appearance varies greatly from case to case. Which is why the diagnosis and classification of malignant peripheral nerve sheath tumor are difficult. Malignant peripheral nerve sheath tumor is a rare type of sarcoma and comprises approximately 5-10% of all soft tissue sarcomas. MPNSTs are quite rare, occurring in 0.001% of the general population. They occur either spontaneously or in association with neurofibromatosis-1 (NF1). Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1. The worldwide incidence rate of malignant peripheral nerve sheath tumor is estimated to be 1.46 per 1,000,000 individuals. Signs and symptoms of malignant peripheral nerve sheath tumor include pain in the affected area, weakness, a growing lump of tissue under the skin.

For requesting free sample and PDF Brochure related to our latest study on Global Malignant Peripheral Nerve Sheath Tumor Treatment Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=8153

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=8153

Furthermore, Meridian Market Consultants (MMC) Study identifies that the estimated lifetime risk of developing malignant peripheral nerve sheath tumor in patients with NF1 is as high as 13%. The treatment options for malignant peripheral nerve sheath tumor as similar to treatment options for other malignant tumors. Surgery is recommended to the removal of the tumor along with surrounding tissue, which may be vital for patient survival. The goal of surgical removal is to achieve complete surgical excision of the tumor with wide margins. Radiation therapy is recommended in pre-operative, intraoperative, and post-operative settings for malignant peripheral nerve sheath tumor. Radiation therapy offers a reduction in local recurrence of a disease. Preoperative external beam radiation therapy is administered before surgical resection. Chemotherapy is recommended for a systemic disease which is either too small to detect or too diffuse and renders local treatment techniques ineffective. Chemotherapy can be administered in the pre-operative and post-operative settings. Commonly prescribed chemotherapy drugs include doxorubicin, dactinomycin, cyclophosphamide, and vincristine.

MMC Study identifies some of the key participating players in malignant peripheral nerve sheath tumor treatment market globally are Pfizer Inc.,  Janssen Pharmaceuticals (Johnson & Johnson), Baxter Healthcare, Alza Pharmaceutical Limited, Sandoz (Novartis AG), Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Recordati Rare Diseases, Inc., Eli Lilly & Co. Ltd., etc. among others.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Improving Treatment Seeking Rate would Drive the Growth of Post-traumatic Stress Disorder Therapy Market

Meridian Market Consultants (MMC) has published a new report titled, “Post Traumatic Stress Disorder Therapy Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Post Traumatic Stress Disorder Therapy Market, by Therapy Type (Psychotherapy-Cognitive Behavioral Therapy, Exposure Therapy, Eye movement desensitisation & reprocessing; Medication), By distribution channels (Hospitals, Clinics, Rehabilitation Centers, others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa)is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Post Traumatic Stress Disorder Therapy Market, click the link below:

https://www.meridianmarketconsultants.com/global-post-traumatic-stress-disorder-therapy-market

As per the report, the incidence of trauma and improving treatment-seeking rates for post-traumatic stress disorder are expected to be prime factors driving the growth of the market. People who have suffered abuse as children or who have had other previous traumatic experiences are more likely to develop. According to the Alcohol, Drug Addiction and Mental Health Services (ADAMHS) Board PTSD affects 3.5% of U.S. adults, and approximately 8 million people in the U.S. are suffering from PTSD. Around 37% of these patients show severe symptoms. Rates of PTSD are found to be higher in women than in men. As per the National Institute of Mental Health (NIMH), study women are four times more likely to develop PTSD than men. The lifetime prevalence of PTSD ranges from 6.1 to 9.2 percent in national samples of the general adult population in the United States and Canada, with one-year prevalence rates of 3.5 to 4.7 percent. A World Health Organization study found a lifetime prevalence of PTSD in upper-middle-income and lower-middle-income countries of 2.3 and 2.1 percent respectively. About 30 percent of the men and women who have spent time in war zones experience PTSD.

For requesting free sample and PDF Brochure related to our latest study on Global Post Traumatic Stress Disorder Therapy Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=9516

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=9516

Furthermore, Meridian Market Consultants (MMC) Study identifies that psychotherapy is expected to contribute to the highest market share in the post-traumatic stress disorder therapy market. Cognitive behavior therapy (CBT) is found to be the most effective psychotherapy for post-traumatic stress disorder. CBT for PTSD is trauma-focused, i.e. the trauma events are the center of the treatment. Trauma-focused CBT is recommended for children and young adults. CBT treatments traditionally occur over 12 to 16 weeks. Eye movement desensitization and reprocessing (EMDR) is a relatively new treatment which is found to relieve symptoms of PTSD. Medication with antidepressants is most commonly prescribed along with psychotherapy. Most commonly prescribed antidepressants for PTSD are paroxetine, mirtazapine, amitriptyline, paroxetine, phenelzine, etc. Of these medications, only paroxetine and sertraline are licensed specifically for the treatment of PTSD. Antidepressants are also prescribed to reduce symptoms of depression, anxiety and sleeping problems. PTSD treatment helps regain a sense of control over a patient’s life.

MMC Study identifies some of the key participating players in post-traumatic stress disorder therapy market globally are Actavis Pharma, Sanis Health Inc., Apotex Corporation, Glaxosmithkline Inc., Merck Ltd., Auro Pharma Inc., Sandoz Inc. (Novartis), Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Par Pharmaceutical, etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Mild Traumatic Brain Injury Market would witness Considerable Growth due to Rising Incidence of Accidental Brain Injuries

Meridian Market Consultants (MMC) has published a new report titled, “Mild Traumatic Brain Injury treatment Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Mild Traumatic Brain Injury treatment Market, by Treatment Type (Pain relievers, Diuretics, Anti-seizure drugs, Coma-inducing drugs), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a healthy CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Mild Traumatic Brain Injury treatment Market, click the link below:

https://www.meridianmarketconsultants.com/global-mild-traumatic-brain-injury-treatment-market

As per the report, increasing incidence of brain injuries due to accidents and the prevalence of neurodegenerative diseases are attributed to growth in mild traumatic brain injury treatment market. As per Department of Neurology, University of California San Francisco, each year 42 million people across the globe suffer from mild traumatic brain injury (MTBI). As per CDC, the incidence of post-traumatic brain injury exceeds 600 per 100,000 people across the globe. Some of the established risk factors for mild traumatic brain injury are Alzheimer's disease, Parkinson's disease, chronic traumatic encephalopathy, and amyotrophic lateral sclerosis (ALS). According to the Alzheimer’s Association, Alzheimer’s disease is a 6th leading cause of death in the U.S> and approximately 5.8 million Americans are suffering from Alzheimer’s disease. In 2019, Alzheimer’s and other dementia are estimated to cost the Nation around US$ 290 billion. Mild traumatic brain injury is acute brain injury resulting from mechanical energy to the head from external physical forces. MTBI is extremely common. It is estimated that 100 to 300 per 100,000 people seek medical attention for MTBI annually worldwide. Improving treatment-seeking rate would thus push the market growth for mild traumatic brain injury treatment.

For requesting free sample and PDF Brochure related to our latest study on Global Mild Traumatic Brain Injury treatment Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=2483

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=2483

Furthermore, Meridian Market Consultants (MMC) Study identifies that specific populations such as contact sport athletes, victims of domestic violence, military personnel, etc. are at the high risk for suffering mild traumatic brain injuries. Treatment for mild traumatic brain injury generally includes symptomatic treatment such as for headaches. Pain relievers such as NSAIDs are prescribed to alleviate pain. Diuretics such as hydrochlorothiazide, torsemide etc. are given to mild traumatic brain injury patients to reduce the amount of body fluids which reduces pressure inside the brain.  People with moderate to severe traumatic brain injury are at the risk of seizures. An anti-seizure drug may be given during the first week to avoid any additional brain damage that might be caused by a seizure. Sometimes coma-inducing drugs such as benzodiazepines are given to the patients of mild traumatic brain injury to relieve pressure on the brain. A comatose brain needs less oxygen to function and this is helpful blood vessels are unable to supply brain cells with nutrients and oxygen.

MMC Study identifies some of the key participating players in mild traumatic brain injury treatment market globally are Sanis Health Inc., Zydus Pharmaceuticals Usa, Inc., Aurobindo Pharma, Cardinal Health, Pfizer Inc., Apotex Corporation, Mylan Institutional Inc., Hoffman La Roche, Valeant Pharmaceuticals, Sandoz (Novartis) etc, among others.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to providing deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Ongoing Clinical Studies for Growth Hormone Therapy in Patients with Rare Disease Achondroplasia would push the market growth for Achondroplasia Treatment Market

Meridian Market Consultants (MMC) has published a new report titled, “Achondroplasia Treatment Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Achondroplasia Treatment Market, by Treatment Type (Growth Hormone therapy, surgery), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Achondroplasia Treatment Market, click the link below:

https://www.meridianmarketconsultants.com/global-achondroplasia-treatment-market

As per the report, the incidence of achondroplasia and launch of new therapies are the prime factor driving the growth of achondroplasia treatment market. Achondroplasia is a rare genetic (inherited) bone disorder that occurs in one in 15,000 to 40,000 live births. Achondroplasia is the most common type of dwarfism, in which the child's arms and legs are short in proportion to body length. Achondroplasia is an autosomal dominant disease. Approximately 80% of achondroplasia cases result from a new mutation in families. In the U.S. approximately 10,000 individuals are estimated to have achondroplasia. The prevalence of achondroplasia in the U.S. ranges from .36 to 0.60 per 10,000 live births. Achondroplasia accounts for 90% of dwarfism or disproportionate short stature. Worldwide prevalence of achondroplasia was found to be 1 in every 25,000–30,000 individuals. That, in turn, translates into around 250,000 affected persons worldwide. The condition affects men and women equally. Studies performed in Texas showed that fathers that >40 years of age had significantly increased rates of de novo achondroplasia among their offspring compared with younger fathers.

For requesting free sample and PDF Brochure related to our latest study on Global Achondroplasia Treatment Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=3751

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=3751

Furthermore, Meridian Market Consultants (MMC) Study identifies that, currently, there is no treatment available to prevent or correct achondroplasia, because the majority of cases result from unexpected new mutations. Long term treatment with growth hormone is recommended. Treatment with growth hormone is continued throughout the teen years and early adulthood to ensure adult maturation, such as appropriate gain in muscle or fat. Some patients may require lifelong therapy. However, treatment with growth hormone does not substantially affect the height of an individual with achondroplasia. In some cases, leg-lengthening surgeries may be considered. Surgeries to correct the spine, or bone problems, as well, as to reduce the pressure inside the brain in cases of hydrocephaly are also recommended. Control of obesity is essential, and obesity can be a significant problem in people with achondroplasia. Some of the ell established brands of growth hormone are Norditropin, Accretropin, Omnitrope, Saizen, Genotropin, Nutropin, Humatrope, etc.

MMC Study identifies some of the key participating players in achondroplasia treatment market globally are WITTENSTEIN SE, Novo Nordisk A/S, Cangene Corporation, Novartis AG, Merck KGaA (Emd Serono), Pfizer Inc. Hoffman La Roche (Genentech), Eli Lilly & Co. Ltd., Ipsen Pharm, Ferring Pharmaceuticals Inc., etc. among others.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Technological Improvements in Stuttering Devices would Push the Market Demand for Stuttering Devices

Meridian Market Consultants (MMC) has published a new report titled, “Stuttering Devices Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Stuttering Devices Market, by Device Type (Delayed Auditory Feedback devices, Electronic fluency devices), By Distribution Channel (Hospital Pharmacy, Clinics, Retail Pharmacy, others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa)is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Stuttering Devices Market, click the link below:

https://www.meridianmarketconsultants.com/global-stuttering-devices-market

As per the report, stuttering is a common speech disorder, and approximately 5% of people will stutter during some part of their lives. Stuttering is characterized by speaking with difficulty and repeating words. Growing incidence of stuttering disorder is one of the major reasons for the growth of stuttering devices market. The highest incidence is seen in preschool-age children with a cumulative rate of 8.5% by 3 years of age and 11% by 4 years of age. The prevalence rate for stuttering across all age groups has been found to be 0.72%. As per Data collected by the Centers for Disease Control and Prevention (CDC), a prevalence rate of stuttering is 1.6% for children between 3 and 17 years of age. Stuttering devices are used to manage stuttering.  Studies have shown that stuttering devices can reduce stuttering by 70%. Stuttering devices work either by delaying the speech feedback or shifting the frequency of the pitch. The device is relatively new but it has been proven capable with significant results. The first stuttering device became available in North America market in 2001. With the help of stuttering devices, stutters can now make public speeches and have smooth conversations without any difficulty.

For requesting free sample and PDF Brochure related to our latest study on Global Stuttering Devices Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=8342

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=8342

Furthermore, Meridian Market Consultants (MMC) Study identifies that latest technological advancements in stuttering devices is expected to push the market growth for stuttering devices market. Stuttering devices have been available for several years, but available technology has been limited in long-term success and reliability. Scientists are evaluating new technologies such as conduction hearing device with delayed auditory feedback on adult patients. These innovative technologies are expected to push the market growth for stuttering devices market. Recently Janus Development Group Inc. announced most substantial product improvement in its SpeechEasy stuttering device. The improved device provides a significant reduction in background noise. The market for stuttering devices is highly fragmented with many small local players operating in the market.

Some of the key participating players identified during the study of global stuttering devices market are Casa Futura Technologies, KayPentax, Janus Development Group Inc., etc. Some of the popular brands of stuttering devices available on the market are SmallTalk DAF/FAF device, SpeechEasy, Brevet etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Increased Penetration of Stem Cell Therapy is expected to Push the Market for Chronic Ocular graft-versus-host Disease

Meridian Market Consultants (MMC) has published a new report titled, “Chronic Ocular Graft-versus-host Disease Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa)is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Chronic Ocular Graft-versus-host Disease Market, click the link below:

https://www.meridianmarketconsultants.com/global-chronic-ocular-graft-%20versus-host-disease-market

As per the report, rapidly growing prevalence of graft versus host disease and increasing number of stem cell transplantation procedures are identified as major factors driving the growth of chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptom. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjuncitvitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis. Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases chances of development of chronic ocular graft versus host disease.

For requesting free sample and PDF Brochure related to our latest study on Global Chronic Ocular Graft-versus-host Disease Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=3892

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=3892

Furthermore, Meridian Market Consultants (MMC) Study identifies that in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation and cord blood transplantation is a routine procedure and it offers a potential cure for life-threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders, etc. Ocular graft-versus-host disease is one of the major complications of allogeneic stem cell transplant. The first-line treatment for chronic ocular graft-versus-host disease includes immunosuppressants and topical steroids. Immunosuppressant treatment for the chronic ocular graft-versus-host disease is methotrexate, cyclosporine, and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being developed such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in the next few years. Amniotic membrane is rich in cytokines, growth factors, and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases the recurrence of the primary condition.

MMC Study identifies some of the key players operating in chronic ocular graft-versus-host disease market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc., etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Global Hemodialysis Machines Market is Driven by Development of New Patient Friendly Hemodialysis Machines

Meridian Market Consultants (MMC) has published a new report titled, “Hemodialysis Machines Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Hemodialysis Machines Market, by Machine Type (Clinical Units, Portable/Home use Machines), By End Users (Hospitals, Clinics, Dialysis Centers, others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Hemodialysis Machines Market, click the link below:

https://www.meridianmarketconsultants.com/global-hemodialysis-machine-market

As per the report, rapidly growing prevalence of end-stage renal disease (ESRD), expanding aging population, technological advances in hemodialysis equipment, are some of the factors pushing the hemodialysis machines market. In the United States, the incidence of ESRD is increasing. Fortunately, both mortality among dialysis patients and the rate at which ESRD has been increasing over the past decade are declining. According to the Center for Disease Control and Prevention (CDC), 726,331 patients in the U.S. being treated with ESRD received hemodialysis, in 2016. The prevalence of dialysis treatment was found to be 1,553 per million. Although the incidence of ESRD is decreasing, prevalence of ESRD has more than doubled in last 25 years. As per the NHS, U.K., over 1.8 million people in England are suffering from chronic kidney disease. In addition, there are thought to be around a million people who have the condition but are undiagnosed. Hemodialysis was first introduced in 1960 and since then market has witnessed tremendous advancements in the hemodialysis techniques and hemodialysis machines. One such development is the introduction of portable hemodialysis machines, which are specially designed for home use or during traveling. These portable dialysis machines have considerably improved quality of life of patients with ESRD.

For requesting free sample and PDF Brochure related to our latest study on Global Hemodialysis Machines Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=7962

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=7962

Furthermore, Meridian Market Consultants (MMC) Study identifies that, the NHS in England spent an estimated £1.45 billion on chronic kidney disease (CKD), equivalent to £1 in every £77 of NHS expenditure. The direct and indirect expenditure on hemodialysis was found to be £505m. Approximately 18,191 patients underwent hemodialysis in England. Hemodialysis technology is rapidly being changed. The hemodialysis technology currently in development is aimed at increasing user-friendliness and connectivity to staff. Besides, many new companies are entering the hemodialysis machines market with their distinguishing technology and innovative machines, which is expected to take the hemodialysis machines market to the next level. For instance, Outset Medical is working on new hemodialysis machine Tablo, which is designed for simplicity. NxStage Medical is working on new home hemodialysis machine System One, which offers higher flow rates than offered today. Baxter’s new home hemodialysis machine, VIVIA, is now undergoing U.S. trials. The system is designed to be patient friendly and will also use the ShareSource connectivity system.

MMC Study identifies some of the key participating players in hemodialysis machines market globally are Fresenius Medical Care, Baxter International, Becton Dickinson and Company (C.R Bard), NxStage Medical Inc., Asahi Kasei Medical Co. Ltd., Nipro, SWS Medical Group, Quanta Dialysis Technologies, B. Braun, Dialife SA, etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Expanding Access to Treatment is Attributed to Growth of Global Iron Metabolism Disorder Drugs Market

Meridian Market Consultants (MMC) has published a new report titled, “Iron Metabolism Disorder Drugs Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Iron Metabolism Disorder Drugs Market, by Indication (Anemia, Haemochromatosis), By Drug Types (Haemochromatosis –further segmented into Desferrioxamine mesilate, Diuretics, ACE Inhibitors; Anemia – further sub-segmented into Iron Supplements, Vitamin B supplements), By Distribution Channel (Hospital Pharmacy, Clinics, Retail Pharmacy, Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Iron Metabolism Disorder Drugs Market, click the link below:

https://www.meridianmarketconsultants.com/global-iron-metabolism-disorders-drugs-market

As per the report, increasing prevalence of anemia and hemochromatosis is attributed to the growth of global iron metabolism disorder drugs market. As per World Health Organisation (WHO), anemia affects approximately 1.62 billion people across the globe. This constitutes a 24.8% population of the world. The highest prevalence of anemia is found in preschool-age children. The highest number of individuals affected with anemia is non-pregnant women. Anemia is defined as a low level of hemoglobin in the blood, as evidenced by fewer numbers of functioning red blood cells. Hemochromatosis is a genetic disorder characterized by increased absorption of dietary iron from intestine. This excess iron accumulates in tissues and organs and interferes with their normal function. According to Haemochromatosis International organization, hemochromatosis is the most common genetic disorder. About 1 in 200 European people have a genetic risk for hemochromatosis. If undetected and untreated hemochromatosis can lead to premature death. Hemochromatosis is often undiagnosed because its symptoms are similar to those caused by a range of other illnesses. Under-diagnosis of hemochromatosis may present challenges to the growth of iron metabolism disorder drugs market. However, if hemochromatosis is detected before damage occurs, it can be easily treated.

For requesting a free sample and PDF Brochure related to our latest study on Global Iron Metabolism Disorder Drugs Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=1485

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=1485

Furthermore, Meridian Market Consultants (MMC) Study identifies that the market for iron metabolism disorder drugs is expected to witness moderate growth over the forecast period. The growth is mainly driven by increased awareness towards iron metabolism disorders treatment and expanding access to treatment. Iron is an essential element for numerous fundamental biologic processes. About 10% of the dietary iron is absorbed each day. Greater iron utilization via growth in childhood, greater iron loss with minor hemorrhages, menstruation in women, and greater need for iron in pregnancy will increase the efficiency of dietary iron absorption to 20%. Iron metabolism is regulated by hepcidin. Fluctuation in hepcidin levels in the body is attributed to the development of iron metabolism disorders. Fluctuation in hepcidin levels can be a result of inflammation or some genetic mutations. Iron metabolism disorder caused due to low levels of iron in the body is treated with iron supplements and vitamin B supplements. Iron metabolism disorder caused by excessive levels of iron in the body such as hemochromatosis is treated with long-term administration of desferrioxamine mesylate. Organ damage due to iron metabolism disorder is treated with diuretics and ACE inhibitors.

Some of the key participating players identified in the study are Pfizer Inc., Novartis AG, Fresenius Kabi, Apopharma Inc., Gland Pharma Limited, Cipla, Abbott, Nestle, Pharmascience Inc., Bedford Pharmaceuticals, etc. among others.

About Meridian Market Consultants:

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Launch of New Treatments to Drive Gastric Cancer Treatment Market

Meridian Market Consultants (MMC) has published a new report titled, “Global Gastric Cancer Treatment Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Gastric Cancer Treatment Market, by Treatment Type (Chemotherapy, Targeted Drugs Therapy, Radiation Therapy), By distribution channels (Hospitals, Clinics, long-term care centers, others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a healthy CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Gastric Cancer Treatment Market, click the link below:

https://www.meridianmarketconsultants.com/global-gastric-cancer-treatment-market

As per the report, the growing prevalence of gastric adenocarcinoma and the availability of new treatment options are the main factors driving the growth of gastric cancer treatment market. According to the American Cancer Society, approximately 27,510 new cases of gastric cancer are expected to be diagnosed in the U.S. in 2019. As per the Globocan registry, globally 1,033,701 new cases of gastric cancer were diagnosed in 2018, and gastric cancer constitutes 5.7% of all new cancer cases. Gastric cancer is usually diagnosed at an advanced stage with distant metastasis. Systemic chemotherapy is the first line of treatment in patients with metastatic gastric adenocarcinoma. 5-fluorouracil is the first chemotherapeutic agent of choice against metastatic gastric adenocarcinoma. Recent advances in treatment such as immune checkpoint inhibitors have achieved a significant increase in response rate to the treatment. However, the cure of metastatic gastric adenocarcinoma is difficult with chemotherapy alone. Current treatment strategies are thus aimed at relieving symptoms and prolong survival. Improving survival rates is another major factor pushing the gastric cancer treatment market. As per the results of the latest clinical trials the median survival rate for metastatic gastric cancer is 6 to 13 months. Expanding aging population is another key factor driving the growth of gastric cancer treatment market. As per American Cancer Society findings of 6 of every 10 people diagnosed with stomach cancer each year are 65 or older.

For requesting free sample and PDF Brochure related to our latest study on Global Gastric Cancer Treatment Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=2947

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=2947

Furthermore, Meridian Market Consultants (MMC) Study identifies that, in spite of the availability of advanced treatment options, gastric adenocarcinoma remains the second highest cause of cancer deaths in the world. Until the late 1930s, stomach cancer was the leading cause of cancer death in the United States. However, the incidence rate for gastric cancer is falling and the rate varies in different geographic regions. Incidence rates are found to be higher in developing countries, and the caseload in developing countries is increasing. Helicobacter pylori (H. pylori) infection is a major risk factor for gastric cancer. Although chemotherapy is recommended primarily for metastatic gastric adenocarcinoma treatment, penetration of new therapies such as targeted therapy with monoclonal antibodies and kinase inhibitors is increasing. FDA Approval of new Immune checkpoint inhibitor therapy in 2018 would further provide traction to the market. The treatment strategy for metastatic gastric adenocarcinoma is considered individually based on the physical and socioeconomic status of patients and on the symptoms. Besides many drugs are being designed to target the molecular pathways involved in the progression of metastatic gastric cancer, which is expected to be launched in the market during the forecast period.

MMC Study identifies some of the key participating players in gastric cancer treatment market globally are Merck, Pfizer, F. Hoffman-La Roche AG, Eli Lilly and Company, Novartis AG, Mylan Pharmaceuticals, Pfizer Inc., Actavis Pharma, Inc., AbbVie etc., among others.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas, 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Barrett’s esophagus coupled with Poor Management of GERD is becoming growing Public Health Concern in Western Countries

Meridian Market Consultants (MMC) has published a new report titled, “Global Barrett’s Esophagus Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Barrette’s Esophagus Market, by Treatment Type (GERD Medicines, Photodynamic Therapy, Radiofrequency Ablation, Endoscopic Mucosal Resection, Esophagectomy), By Treatment Providers (Hospitals, Ambulatory Surgical Center, Clinics), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Barrett’s Esophagus Market, click the link below:

https://www.meridianmarketconsultants.com/global-barrett-esophagus-market

As per the report, growing prevalence of gastroesophageal reflux disease (GERD) and poor management of GERD are prime factors driving growth of Barrette’s esophagus treatment market. Barrett’s esophagus is a serious complication chronic of chgastroesophageal reflux disease, and its high prevalence is leaving significant economic impact on global healthcare system. According to US Surveillance Epidemiology and End Results (SEER), 10% of the GERD patients develop Barrett’s esophagus. Low treatment rate for GERD is another major factor leading to the increased prevalence of Barrett’s esophagus. Risk factors for the development of Barrett’s disease also include obesity and tobacco smoking, but GERD is the major risk factor. Costs due to poorly treated GERD with Barrett’s esophagus represent a substantial burden for the healthcare systems. For instance, according to study conducted by Universitat de Barcelona and University of Naples Italy, the estimated cost for the healthcare systems for the population with poorly treated GERD with Barrett’s esophagus was found to be €18 million in Spain, € 12 million in Germany and € 7 million in Germany, in 2015. Furthermore, improving diagnosis rates for Barrett’s esophagus is expected to drive the market for Barrett’s esophagus over the forecast period. A study from Mayo clinic suggests that the concurrent increase number of endoscopies performed annually has improved the ability to diagnose Barrett’s esophagus.

For requesting free sample and PDF Brochure related to our latest study on Global Barrett’s Esophagus Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=9574

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=9574

Furthermore, Meridian Market Consultants (MMC) Study identifies that, in 2011, the population with poorly treated GERD with Barrett’s esophagus was estimated to be 29,678 in Spain, 19,327 in Germany and 10,079 in Italy. Barrett’s esophagus is a precursor of esophageal adenocarcinoma (EAC) incidence of which has dramatically increased in past four decades. Although EAC is classified as a rare cancer, it is the most rapidly rising cancer in the U.S. Barrett’s esophagus is primarily observed in the older adults of the developed countries such as U.S. and European countries. Barrett's esophagus is two to three times more common in men than in women. The exact prevalence of Barrett’s esophagus in living adults is difficult to find, because patients with Barrett’s esophagus are often asymptomatic. The prevalence of the Barrett’s esophagus can be estimated based on findings of upper endoscopy procedures. Treatment options for Barrett’s esophagus include medicines for GERD, endoscopic mucosal resection, photodynamic therapy, ablation therapy and surgery etc. Most doctors recommend periodic surveillance endoscopy with biopsy to monitor signs of cancer. Endoscopic ablation therapies use different techniques to destroy dysplasia – abnormal cells developed in esophagus. Photodynamic therapy uses light-activated chemical and laser to destroy precancerous cells in the esophagus.  

MMC Study identifies some of the key participating players in Barrett’s esophagus market globally are GlaxoSmithKline Plc., Pfizer Inc., AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Johnson and Johnson, Eisai Inc., Takeda Pharmaceuticals etc. among others,

About Meridian Market Consultants:

Meridian Market Consultants is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

 Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[meridianmarketconsultants-blog]

Meridian Market Consultants brings you an opportunity to view and analyze the data sets for maintaining the healthy growth spectrum of the company

[meridianmarketconsultants-blog]

Anti-Idiopathic pulmonary fibrosis emerges as an important public health disturbance globally that is serving as increased emphasis on novel drug innovations in the market

Meridian Market Consultants (MMC) has published a new report titled, “Anti-Idiopathic Pulmonary Fibrosis Drugs Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Overview

An overview of conceptual frameworks, analytical approaches of the Anti-Idiopathic Pulmonary Fibrosis Drugs Market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Anti-Idiopathic Pulmonary Fibrosis Drugs Market is expected to grow with significant rate in the near future.

MMC Overview

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

Request to View Sample of Report: https://www.meridianmarketconsultants.com/requst?rid=6954

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Dynamics

Growing prevalence of idiopathic pulmonary fibrosis (IPF), coupled with increasing geriatric population across the globe are major factors that are expected to drive the growth of the global anti-idiopathic pulmonary fibrosis drugs market during the forecast period. For instance, according to the World Population Aging Report 2015 by United Nations, total population aged 60 years and above is expected to grow by 56%, i.e., from 901 Mn in 2015 to 1.4 Bn in 2030. Also, commercialization of novel drugs is another important factor boosting growth of the target market. Furthermore, surge in cigarette smoking population is expected to propel the growth of the market in the near future. Moreover, presence of strong pipeline provided by the government for the treatment is likely to increase the growth of global anti-idiopathic pulmonary fibrosis drugs market. However, unknown disease etiology, there is no specific cure for idiopathic pulmonary fibrosis, which is restraining the growth of the target market.

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation

Anti-idiopathic pulmonary fibrosis drugs market is segmented on the basis of market drugs, mechanism of action, innovator and off-label drugs, and by region.

By Marketed Drugs:

Esbriet

Ofev

By Mechanism of Action:

Antifibrotics

Tyrosine Kinase Inhibitors

Anti-Inflammatory Drugs

Immunosuppressant’s

Others

By Innovator and Off-Label Drugs:

Innovator Drugs

Off-Label Drugs

By Region:

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Overview

More than 200 diseases related to lungs are mainly belongs to Idiopathic pulmonary fibrosis (IPF) which is known as interstitial lung diseases (ILDs), which is characterized by the involvement of the tissues which are found in between air sacs of the lung also known as lung interstitium. IPF is one specific presentation of idiopathic interstitial pneumonia (IIP), which is in turn a type of ILD, also called diffuse parenchymal lung disease (DPLD). Idiopathic pulmonary fibrosis (IPF) is a progressive disease in which lungs get affected and gets scars and marks in tissues and affect lungs performance in a negative manner. Persistent non-productive cough and dyspnea are most common symptoms and signs of idiopathic pulmonary fibrosis. Also, gradual weight loss and loss of appetite is also found in many individuals due to the idiopathic pulmonary fibrosis. IPF mainly occurs in older adults. However, the causes are unknown. It has been noted that idiopathic pulmonary fibrosis is prevailing more in smoking population. People also suffer from lung diseases due to second hand smoking which is the smoke that fills restaurants, offices or other enclosed spaces when people burn tobacco products such as cigarettes, bidis and water-pipes. According to study done by WHO, in May 2019, In adults, second-hand smoke causes serious cardiovascular and respiratory diseases, including coronary heart disease and lung cancer. In infants, it raises the risk of sudden infant death syndrome. In pregnant women, it causes pregnancy complications and low birth weight. Second-hand smoke causes more than 1.2 million premature deaths per year. Also more than 65,000 children die every year from illnesses attributable to second-hand smoke.

Request to View PDF Brochure of Report: https://www.meridianmarketconsultants.com/pdf?rid=6954

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Competitive Landscape

Some of the key participating players in anti-idiopathic pulmonary fibrosis drugs market are Actelion, Afferent Pharmaceuticals, Asahi Kasei Pharma, Bellerophon Therapeutics, Biogen, Boehringer Ingelheim, FibroGen, Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, and Kadmon Pharmaceuticals and others.

Regional Segmentation:

On the basis of region, the anti-idiopathic pulmonary fibrosis drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

 Contact Us

Meridian Market Consultants

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

Email: sales@meridianmarketconsultants.com

For More Info: Info@meridianmarketconsultants.com  

Website: http://www.meridianmarketconsultants.com